What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow-up? A systematic review and secondary analysis of a randomised controlled trial

Health Technology Assessment

Volumn 21, Issue 22, 2017, Pages

  Shinkins, Bethany ^a   Nicholson, Brian D ^a   James, Tim ^b   Pathiraja, Indika ^a   Pugh, Sian ^c   Perera, Rafael ^a   Primrose, John ^c   Mant, David ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN;

BIOMEDICAL TECHNOLOGY ASSESSMENT; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RESEARCH; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; EMERGENCY HEALTH SERVICE; ENGLAND; FEASIBILITY STUDY; FOLLOW UP; HUMAN; MEDICAL DECISION MAKING; META ANALYSIS; METASTASIS; NATIONAL HEALTH SERVICE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; REVIEW; SECONDARY ANALYSIS; SENSITIVITY AND SPECIFICITY; SMOKING; STATISTICAL BIAS; SYSTEMATIC REVIEW; TREND STUDY; BLOOD; CLINICAL TRIAL; COLORECTAL TUMOR; MULTICENTER STUDY; PATHOLOGY; PREDICTIVE VALUE; TUMOR RECURRENCE;

CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; STATE MEDICINE; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 85021272473     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta21220     Document Type: Review

References (41)

1. Duffy MJ, Lamerz R, Haglund C, Nicolini A, Kalousová M, Holubec L, Sturgeon C. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer 2014;134:2513–22. http://dx.doi.org/10.1002/ijc.28384
2. Labianca R, Nordlinger B, Beretta GD, Brouquet A, Cervantes A, ESMO Guidelines Working Group. Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol 2010;21(Suppl. 5):70–7. http://dx.doi.org/10.1093/annonc/mdq168
3. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313–27. http://dx.doi.org/10.1200/JCO.2006.08.2644
4. Freedman-Cass D, Gregory KM. Clinical Practice Guidelines in Oncology (NCCN Guidelines): Colon Cancer. Fort Washington, PA: National Comprehensive Cancer Network Foundation; 2016.
5. National Institute for Health and Care Excellence. Colorectal Cancer: Diagnosis and Management. NICE clinical guideline 131. URL: www.nice.org.uk/guidance/cg131/chapter/1-recommendations 2011 (accessed 5 December 2015).
6. Sturgeon CM, Lai LC, Duffy MJ. Serum tumour markers: how to order and interpret them. BMJ 2009;339:b3527. http://dx.doi.org/10.1136/bmj.b3527
7. Newton KF, Newman W, Hill J. Review of biomarkers in colorectal cancer. Colorectal Dis 2012;14:3–17. http://dx.doi.org/10.1111/j.1463-1318.2010.02439.x
8. Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 2005;23:338–51. http://dx.doi.org/10.1081/CNV-58878
9. Scheer A, Auer RA. Surveillance after curative resection of colorectal cancer. Clin Colon Rectal Surg 2009;22:242–50. http://dx.doi.org/10.1055/s-0029-1242464
10. Tsikitis VL, Malireddy K, Green EA, Christensen B, Whelan R, Hyder J, et al. Postoperative surveillance recommendations for early stage colon cancer based on results from the clinical outcomes of surgical therapy trial. J Clin Oncol 2009;27:3671–6. http://dx.doi.org/10.1200/JCO.2008.20.7050
11. Jeffery M, Hickey BE, Hilder PN. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 2007;1:CD002200. http://dx.doi.org/10.1002/14651858.cd002200.pub2
12. Primrose JN, Perera R, Gray A, Rose P, Fuller A, Corkhill A, et al. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA 2014;311:263–70. http://dx.doi.org/10.1001/jama.2013.285718
13. Tan E, Gouvas N, Nicholls RJ, Ziprin P, Xynos E, Tekkis PP. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg Oncol 2009;18:15–24. http://dx.doi.org/10.1016/j.suronc.2008.05.008
14. Glasziou P, Irwig L, Mant D. Monitoring in chronic disease: a rational approach. BMJ 2005;330:644–8. http://dx.doi.org/10.1136/bmj.330.7492.644
15. Cochrane Diagnostic Review Group Quality Criteria. URL: http://methods.cochrane.org/sdt/handbook-dta-reviews (last accessed 5 November 2016).
16. Nicholson BD, Shinkins B, Pathiraja I, Roberts NW, James TJ, Mallett S, et al. Blood CEA levels for detecting recurrent colorectal cancer. Cochrane Database Syst Rev 2015;12:CD011134.http://dx.doi.org/10.1002/14651858.CD011134.pub2
17. Shinkins B, Nicholson BD, Primrose J, Perera R, James T, Pugh S, et al. The diagnostic accuracy of a single CEA blood test in detecting colorectal cancer recurrence: results from the FACS trial. PLOS ONE 2017;12:e0171810.
18. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS–2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;55:529–36. http://dx.doi.org/10.7326/0003-4819-155-8-201110180-00009
19. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005;58:982–90. http://dx.doi.org/10.1016/j.jclinepi.2005.02.022
20. Takwoingi Y. Meta-Analysis of Test Accuracy Studies in Stata: A Bivariate Model Approach. Version 1. URL: http://methods.cochrane.org/sites/methods.cochrane.org.sdt/files/public/uploads/Chapter% 2010%20-%20Version%201.0.pdf (accessed 6 November 2016).
21. Sargent DJ, Patiyil S, Yothers G, Haller DG, Gray R, Benedetti J, et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol 2007;25:4569–74. http://dx.doi.org/10.1200/JCO.2006.10.4323
22. Agency for Healthcare Research and Quality. National Guideline Clearing House. Follow-Up of Colorectal Cancer or Polyps. URL: www.guideline.gov/summaries/summary/46911 (accessed 5 November 2016).
23. Laurence DJ, Turberville C, Anderson SG, Neville AM. First British standard for carcinoembryonic antigen (CEA). Br J Cancer 1975;32:295–9. http://dx.doi.org/10.1038/bjc.1975.227
24. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 1993;12:1293–316. http://dx.doi.org/10.1002/sim.4780121403
25. Cochrane. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy. URL: http://methods.cochrane.org/sdt/handbook-dta-reviews (accessed 5 November 2016).
26. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Müller M. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011;12:77. http://dx.doi.org/10.1186/1471-2105-12-77
27. Shinkins B, Nicholson BD, James TJ, Primrose JN, Mant D. Carcinoembryonic antigen monitoring to detect recurrence of colorectal cancer: how should we interpret the test results? Clin Chem 2014;60:1572–4. http://dx.doi.org/10.1373/clinchem.2014.228601
28. Su BB, Shi H, Wan J. Role of serum carcinoembryonic antigen in the detection of colorectal cancer before and after surgical resection. World J Gastroenterol 2012;18:2121–6. http://dx.doi.org/10.3748/wjg.v18.i17.2121
29. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109–16. http://dx.doi.org/10.1200/JCO.2008.20.6771
30. Minton JP, Martin EW. The use of serial CEA determinations to predict recurrence of colon cancer and when to do a second-look operation. Cancer 1978;42(Suppl. 3):1422–7. http://dx.doi.org/10.1002/1097-0142(197809)42:3+<1422::AID-CNCR2820420807>3.0.CO;2-1
31. Staab HJ, Anderer FA, Stumpf E, Hornung A, Fischer R, Kieninger G. Eighty-four potential second-look operations based on sequential carcinoembryonic antigen determinations and clinical investigations in patients with recurrent gastrointestinal cancer. Am J Surg 1985;149:198–204. http://dx.doi.org/10.1016/S0002-9610(85)80064-7
32. Carl J, Bentzen SM, Nørgaard-Pedersen B, Kronborg O. Modelling of serial carcinoembryonic antigen changes in colorectal cancer. Scand J Clin Lab Invest 1993;53:751–5. http://dx.doi.org/10.3109/00365519309092581
33. Boey J, Cheung HC, Lai CK, Wong J. A prospective evaluation of serum carcinoembryonic antigen (CEA) levels in the management of colorectal carcinoma. World J Surg 1984;8:279–86. http://dx.doi.org/10.1007/BF01655052
34. Verberne CJ, Zhan Z, van den Heuvel E, Grossmann I, Doornbos PM, Havenga K, et al. Intensified follow-up in colorectal cancer patients using frequent carcino-embryonic antigen (CEA) measurements and CEA-triggered imaging: results of the randomised ‘CEAwatch’ trial. Eur J Surg Oncol 2015;41:1188–96. http://dx.doi.org/10.1016/j.ejso.2015.06.008
35. Grossmann I, Verberne C, De Bock G, Havenga K, Kema I, Klaase J. The role of High frequency Dynamic Threshold (HiDT) Serum Carcinoembryonic antigen (CEA) measurements in colorectal cancer surveillance: a (revisited) hypothesis paper. Cancers 2011;3:2302–15. http://dx.doi.org/10.3390/cancers3022302
36. Huang YY, Lee PI, Liu MC, Chen CC, Huang KC, Huang AT. A general cutoff level combined with personalised dynamic change of serum carcinoembryonic antigen can suggest timely use of FDG PET for early detection of recurrent colorectal cancer. Clin Nucl Med 2015;40:e465–9. http://dx.doi.org/10.1097/RLU.0000000000000900
37. Ito K, Hibi K, Ando H, Hidemura K, Yamazaki T, Akiyama S, Nakao A. Usefulness of analytical CEA doubling time and half-life time for overlooked synchronous metastases in colorectal carcinoma. Jpn J Clin Oncol 2002;32:54–8. http://dx.doi.org/10.1093/jjco/hyf011
38. Litvak A, Cercek A, Segal N, Reidy-Lagunes D, Stadler ZK, Yaeger RD, et al. False-positive elevations of carcinoembryonic antigen in patients with a history of resected colorectal cancer. J Natl Compr Canc Netw 2014;12:907–13.
39. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice E6(R1). 1996. URL: www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf (accessed 6 November 2016).
40. European Parliament and Council. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the Approximation of the Laws, Regulations and Administrative Provisions of the Member States Relating to the Implementation of Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Human Use. URL: http://ec.europa.eu/health/files/eudralex/vol-1/dir_2001_20/dir_2001_20_en.pdf (accessed 6 November 2016).
41. NHS NIHR Research Governance Framework. URL: www.nihr.ac.uk/policy-and-standards/framework-for-research-support-services.htm (accessed 6 November 2016).